L-DOPA and graft-induced dyskinesia: different treatment, same story?

Ludivine S Breger, Emma L Lane
Exp Biol Med (Maywood). 2013-07-01; 238(7): 725-732
DOI: 10.1177/1535370213488478

Lire sur PubMed

1. Exp Biol Med (Maywood). 2013 Jul;238(7):725-32. doi: 10.1177/1535370213488478.
Epub 2013 Jul 4.

L-DOPA and graft-induced dyskinesia: different treatment, same story?

Breger LS(1), Lane EL.

Author information:
(1)School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff,
CF10 3NB, UK.

One of the well-recognized problems of long-term L-3,4-dihydroxyphenylalanine
(L-DOPA) therapy in the treatment of Parkinson’s disease is the development of
L-DOPA induced dyskinesia. These abnormal movements cause significant disability
and narrow the therapeutic window of L-DOPA. Cell transplantation is one of the
most promising upcoming therapies for the treatment of Parkinson’s disease, and
may help alleviate or avoid L-DOPA-induced dyskinesia. However, the more recently
acknowledged phenomenon of graft-induced dyskinesia is posing a major obstacle to
the success of this treatment. This motor side-effect closely resembles abnormal
movements induced by chronic L-DOPA treatment, yet they remain after withdrawal
of the medication indicating their origins lie in the transplant. In this review,
we compare these two therapy-induced adverse effects, from the way they manifest
in patients to the possible mechanisms underlying their development.

DOI: 10.1177/1535370213488478
PMID: 23828589 [Indexed for MEDLINE]

Auteurs Bordeaux Neurocampus